FIELD: medicine.
SUBSTANCE: invention can be used for treating Trop-2-positive cancer in a patient. That is ensured by administering an antibody-drug conjugate (ADC) to a human patient with Trop-2-positive cancer. Patient has relapsed after treatment with a control point inhibitor or refractory treatment to a control point inhibitor. Said ADC contains SN-38 conjugated with linker fragment attached to antibody to Trop-2 or its antigen-binding fragment. Antibody is the hRS7 antibody. Said linker is CL2A. ADC has structure MAb-CL2A-SN-38.
EFFECT: invention provides treating the patients with Trop-2-positive cancer resistant to the control point inhibitors treatment.
21 cl, 11 tbl, 5 dwg, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPY OF METASTATIC UROTHELIAL CANCER USING ANTIBODY-DRUG CONJUGATE SATSITUZUMAB GOVITECAN (IMMU-132) | 2017 |
|
RU2757395C2 |
| TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER CHARACTERIZED BY Trop-2 EXPRESSION USING SATSITUZUMAB GOVITECAN AND Rad51 INHIBITOR | 2018 |
|
RU2758234C2 |
| CONJUGATE OF TROP-2 ANTIBODY AND EXATECAN ANALOGUE AND MEDICAL USE THEREOF | 2021 |
|
RU2830167C1 |
| ANTI-c-MET DRUG CONJUGATE AND USE THEREOF | 2021 |
|
RU2822497C1 |
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
| DUOCARMYCIN ADCs EXHIBITING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2769700C2 |
| HUMANISED ANTIBODIES TO LIV-1 AND USE THEREOF FOR TREATING CANCER | 2011 |
|
RU2608646C2 |
| ANTI-TROP2 ANTIBODY-DRUG CONJUGATE | 2014 |
|
RU2705367C2 |
| ANTIBODY-DRUG CONJUGATES WITH HIGH DRUG LOADING | 2015 |
|
RU2674979C2 |
| METHOD FOR DETERMINING THERAPEUTIC APPROACH IN PATIENTS WITH METASTATIC FORMS AND RECURRENT TRIPLE-NEGATIVE BREAST CANCER | 2023 |
|
RU2818730C1 |
